ALKERMES | ALKS - 营业费用

金融业

USD

USD 4.26B

现金及等价物

USD 351.55M

USD 73.25M

USD 1.36B

USD 599.5M

USD 1.58B

股息收益率

0

USD -48.28M

USD 80.26M

1.8K

EPS每股收益

USD -0.4

股本和储备

USD 1.75B

USD 331.33M

债务利息支出

USD 20.89M

USD 8.54M

USD 1.48B

USD 6.02B

USD -66.48M

USD 1.75B

USD -48.28M

普通股股本

USD 166.46M

39.33

USD -61.93M

USD 392.91M

销售和管理费用

USD 264.59M

USD 336.7M

贸易债权人

USD 102.36M

应收帐款人

USD 407.63M

	营业费用	更改		日
AbbVie	USD 10.27B		538M	2026-03
Acadia Pharmaceuticals	USD 272.68M		6.08M	2026-03
ALKERMES	USD 1.75B		1.43B	2026-03
Amgen	USD 4.78B		1.12B	2026-03
Biogen	USD 1.96B		69.6M	2026-03
BioMarin Pharmaceutical	USD 636.56M		39.61M	2026-03
Bristol-Myers Squibb	USD 20.07B		11.77B	2026-03
Coherus Biosciences	USD 51.83M		2.48M	2025-12
Eli Lilly	USD 10.02B		285M	2026-03
Gilead Sciences	USD 23.52B		18.55B	2026-03
Heron Therapeutics	USD 40.55M		1.46M	2025-12
Ionis Pharmaceuticals	USD 364M		54M	2026-03
J&J	USD 17.44B		1.53B	2026-03
Malin Corporation	EUR 1.1M		400K	2024-12
Merck	USD 18.17B		8.01B	2026-03
Minerva Neurosciences	USD 4.52M		155.46K	2024-12
Nektar Therapeutics	USD 40.9M		44.19M	2025-12
Neurocrine Biosciences	USD 599.9M		22.3M	2026-03
Otsuka Holdings	JPY 512.13B		70.77B	2026-03
Ovoca Bio	EUR 1.16M		4.48M	2025-06
Pfizer	USD 90.1B		77.19B	2026-03
Regeneron Pharmaceuticals	USD 31.42B		28.44B	2026-03
Vertex Pharmaceuticals	USD 1.85B		78.6M	2026-03